The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Robert S Poston; Charles White; Junyan Gu; James Brown; James Gammie; Richard N Pierson; Andrew Lee; Ingrid Connerney; Thrity Avari; Robert Christenson; et al. (Profiled Authors: James S Gammie; Bartley P Griffith; Richard N Pierson III; Charles S White; Robert H Christenson)
Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. firstname.lastname@example.org
The Annals of thoracic surgery 2006;81(1):104-10; discussion 110-1.
BACKGROUND: Hemostatic drugs are widely thought to be unnecessary and potentially detrimental in off-pump coronary artery bypass graft surgery (OPCABG), despite well-established use in on-pump surgery. In a randomized, prospective OPCABG trial, we assessed efficacy and safety of aprotinin through a comprehensive assessment of graft patency and hematologic function. METHODS: Sixty patients were randomly assigned to full-dose aprotinin or placebo. Heparin was titrated to a kaolin-based activated clotting time of greater than 300 seconds. Exclusionary criteria included creatinine greater than 2 mg/dL, conversion to on-pump CABG, and preoperative GPIIb/IIIa inhibition. Hematologic assessments were obtained preoperatively, at the end of surgery, and on days 1 and 3: mean platelet volume, thrombin generation (prothrombin fragment 1.2 assay), and aspirin resistance using a modified thrombelastography, whole blood aggregometry, 11-dehydro-thromboxane B2 levels, and flow cytometry. Thrombotic events were defined as postoperative myocardial infarction by electrocardiography or elevated troponin I, clinical stroke by examination and head computed tomography, and bypass graft failure by multichannel computed tomography angiography on day 5. RESULTS: Aprotinin was associated with a significant reduction in intraoperative and postoperative blood loss compared with placebo but had no effect on transfusion rates. Patients treated with aprotinin had significantly fewer thrombotic events (3% versus 23%, p < 0.05, Fisher's exact test) and less postoperative aspirin resistance (20% versus 46%, respectively, p < 0.05, Fisher's exact test). Postoperative prothrombin fragment 1.2 level was reduced by aprotinin use. CONCLUSIONS: Aprotinin reduced perioperative bleeding after OPCABG. Preserved aspirin sensitivity in the aprotinin group may explain the observed reduction in thrombotic events and might be related to the suppression of perioperative and transmyocardial thrombin formation.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Pranjal H Desai; Dinesh Kurian; Nannan Thirumavalavan; Sneha P Desai; Pluen Ziu; Michael Grant; Charles White; R Clive Landis; Robert S PostonAnesthesia and analgesia 2009;109(5):1387-94.
Robert Poston; Junyan Gu; Jeffrey Manchio; Andrew Lee; James Brown; James Gammie; Charles White; Bartley P GriffithEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2005;27(4):584-91.
Robert S Poston; Junyan Gu; Charles White; Jean Jeudy; Lei Nie; James Brown; James Gammie; Richard N Pierson; Linda Romar; Bartley P GriffithTransfusion 2008;48(1 Suppl):39S-46S.
Appears in this Publication
Author of this Publication